Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses

Conclusions: [225Ac]Pr and its imaging biomarker [111In]Pr demonstrate optimal radiopharmacologic behavior for theranostic applications of α-DOTA-PRIT. For this initial evaluation of efficacy and toxicity, single-cycle treatment regimens were performed in all three systems. Histologic toxicity was not observed, so MTD was not observed. Prolonged overall survival, CRs, and histologic cures were observed in treated animals. In comparison to RIT with anti-tumor IgG antibodies, [225Ac]Pr has a much improved safety profile. Ultimately, these data will be used to guide clinical development of toxicity and efficacy studies of [225Ac]Pr, with the goal of delivering massive lethal doses of radiation to achieve a high probability of cure without toxicity.

Source: Theranostics - October 3, 2020 Category: Molecular Biology Authors: Sarah M. Cheal, Michael R. McDevitt, Brian H. Santich, Mitesh Patel, Guangbin Yang, Edward K. Fung, Darren R. Veach, Meghan Bell, Afruja Ahad, Daniela Burnes Vargas, Blesida Punzalan, Naga Vara Kishore Pillarsetty, Hong Xu, Hong-fen Guo, S é bastien Mone Tags: Research Paper Source Type: research